Forward-Looking Statements

The forward-looking statements contained on this website are based on management’s expectations and beliefs as of the date of publication and are subject to risks, uncertainties and assumptions. Actual results may differ materially from those described. Except for statements of historical fact, statements on this website may constitute forward-looking statements, including estimates and expectations concerning financial measures, legal or regulatory outcomes, clinical development, patient and prescribing patterns, reimbursement outcomes and other matters. Forward-looking statements involve significant risks and uncertainties, some of which are discussed in this statement and described more fully in the Company’s reports filed with The Stock Exchange of Hong Kong Limited. Unless otherwise required by applicable law or the Hong Kong Listing Rules, the Company undertakes no obligation to update any forward-looking statements.

Forward-looking statements do not guarantee future results. The discovery of new product candidates, the identification of new indications for existing products, and the advancement of concepts into products are all subject to uncertainty. There can be no assurance that any product candidate or new indication will be successfully developed and ultimately brought to market. Preclinical results do not guarantee the safety and efficacy of a product in humans; animal models or cell culture systems cannot fully replicate the complexity of the human body. The Company develops product candidates through internal research and development, licensing, collaborations and joint ventures. Product candidates developed in collaboration with other parties may be affected by disputes among the parties or may fail to achieve the efficacy or safety anticipated at the outset of the collaboration. Even after a product is marketed, the Company or third parties may identify safety concerns, adverse effects or manufacturing issues. The Company’s business may be affected by compliance risks arising from government investigations, litigation, product liability claims and controversial market practices. Manufacturing capacity for certain existing or future products depends on third parties, and supply constraints may limit product sales and the development of product candidates.